$40 Million

Tenax Therapeutics

At-the-market Offering

Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing and commercializing products for the critical care market. The company develops novel product candidates such as Levodimendan IV that have the potential to address various critical care conditions with a high unmet medical need. Its drugs help in the reduction of morbidity and mortality in cardiac surgery patients. Levosimendan is a calcium sensitizer/K-ATP activator developed for intravenous use in hospitalized patients with acutely decompensated heart failure.